The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Official Title: A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Study ID: NCT00171704
Brief Summary: Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.
Detailed Description:
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Novartis Investigative Site, Aalborg, , Denmark
Novartis Investigative Site, Arhus, , Denmark
Novartis Investigative Site, Copenhagen, , Denmark
Novartis Investigative Site, Esbjerg, , Denmark
Novartis Investigative Site, Herlev, , Denmark
Novartis Investigative Site, Herning, , Denmark
Novartis Investigative Site, Hillerod, , Denmark
Novartis Investigative Site, Kløvervænget, , Denmark
Novartis Investigative Site, Roskilde, , Denmark
Novartis Investigative Site, Sonderborg, , Denmark
Novartis Investigative Site, Vejle, , Denmark
Novartis Investigative Site, Viborg, , Denmark
Novartis Investigative Site, Sheffield, , United Kingdom
Name: Novartis
Affiliation: Novartis
Role: STUDY_CHAIR